A S THE NATION'S BIOMEDICAL RESEARCH AGENCY, THE
National Institutes of Health (NIH) must ensure that the research it funds on the behalf of US tax payers is scientifically rigorous and free of bias. Over the course of more than 65 years and hundreds of thou sands of awards, most researchers receiving funds from NIH have proved to be trustworthy stewards. Still, more must be done to retain, and in some instances regain, public trust in the biomedical and behavioral research enterprise.
The public may not always understand the intricacies of rigorous science, but most individuals quickly grasp the con cept of bias. Plain and simple, Americans do not want fi nancial conflicts of interest (FCOI) to influence the feder ally funded research they hope will yield better ways to fight disease and improve health.
Managing FCOI in biomedical and behavioral research, however, can prove to be a major challenge because of the complex relationships among government, academia, and industry. Partnerships between NIH-funded researchers and industry are often essential to the process of moving dis coveries from the bench to the bedside. These relation ships manifest as consultant agreements, in published works, and through a variety of other productive alliances. How ever, such relationships can sometimes lead to FCOI that may compromise-or appear to compromise-the integ rity of research supported by NIH.
The US Public Health Service, of which NIH is a part, is the only federal agency to have regulations regarding FCOI in research. 1 In addition to the individual responsibilities ascribed to NIH-funded investigators, institutions that re ceive NIH funding have responsibilities to develop policies to implement the regulations and to adhere to such poli cies. In recent years, it has become increasingly apparent that the existing federal regulations, which were promul gated in 1995, need to be clarified and strengthened to en sure greater transparency and accountability. Without such changes, even more instances of real or perceived FCOI will likely be encountered in the future.
The following scenarios, which incorporate various ele ments of real-life cases, illustrate some of the many chal lenges that need to be addressed. University X. The principal investigator of an NIHsupported clinical trial at university X fails to disclose more than $750 000 in payments for serving on an advisory panel for a company involved in the trial. Although the re searcher followed the university's policies concerning fi nancial disclosure, NIH suspends the trial and requires all grant applications from university X to include details of in vestigators' FCOI. Subsequently, university X develops and implements new processes for managing FCOI. NIH lifts the special award conditions. Investigator Y. Because she is an NIH grantee, investi gator Y discloses to her university that she received lecture fees of "more than $10 000" annually over the past decade from a company developing a drug based on her laborato ry's findings. In fact, investigator Y receives more than $500 000 annually in such fees. However, investigator Y does not violate her university's policy or the current federal rules because they do not require researchers to identify the pre cise amounts received from drug makers. The university de cides to revise its FCOI policy.
Institution Z. NIH imposes special conditions on all grant awards to institution Z, citing deficiencies in its FCOI rules. The action follows institution Z's failure to report to NIH more than $1 million in company payments that a re searcher received for promoting a new diagnostic test. The NIH-supported investigator fulfilled institution Z's disclo sure requirements, but those requirements were not in com pliance with federal regulations. An ensuing investigation by institution Z finds that the researcher had no actual FCOI related to his NIH-supported research. Still, institution Z works with NIH to revise its policy and procedures to en sure they are consistent with federal regulations.
Time for Change
Clearly, investigators, institutions, and NIH need to re double collaborative efforts to uphold the integrity of fed erally funded biomedical and behavioral research. If NIHsupported researchers fail to disclose the full extent of their financial interests, universities fail to comprehensively man age FCOI, or NIH fails to diligently oversee the entire sys-tem, public trust will be jeopardized in ways that may have far-reaching implications for the future of science.
To reduce ambiguities in the current regulations and keep bias out of federally funded biomedical and behavioral re search, NIH has sought extensive public input and labored for more than a year to develop a proposal for a revised regu lation that more precisely spells out the roles of NIH, of grantee institutions, and of investigators in disclosing, iden tifying, and managing FCOI.
In
Current Regulations
To grasp the rationale behind the proposed rule changes, it helps to consider the current regulations. Under this regu latory framework, most of the responsibility for disclosing significant financial interests that could pose possible FCOI lies with individual investigators, not their institutions. Spe cifically, investigators determine and disclose to their in stitutions any significant financial interest that would rea sonably appear to be affected by the NIH-supported research, as well as any significant financial interest involving enti ties whose financial interests would reasonably appear to be affected by the research. Institutions, in turn, are re quired to manage, reduce, or eliminate the conflict; to re port to NIH; and to assure NIH that this process has been followed for all identified FCOI that could have a signifi cant and direct effect on NIH-funded research.
Proposed Rules
In the revised regulations, NIH seeks to make changes in several key areas that would enhance regulatory compli ance, strengthen NIH and institutional oversight, and ex pand transparency (TABLE) . First, the proposed regula tions would require that NIH-funded investigators disclose to their institutions all significant financial interests re lated to their institutional responsibilities. This would move the responsibility for determining if an investigator's sig nificant financial interests are related to NIH-supported re search from the investigator to his or her institution. The proposal would also lower the monetary threshold at which interests require disclosure, generally from $10 000 to $5000.
Second, the proposed regulations would require institu tions to develop a management plan for every identified FCOI, which may include reduction or elimination of the FCOI. The institution would be required to provide to NIH significant additional information on identified FCOI and their management.
The third major area of change centers on transparency. The proposed rules would require every NIH-funded insti tution to post, on a publicly accessible Web site, informa tion on certain significant financial interests that the insti tution has determined are related to NIH-funded research 
Topic

Current Proposed
Significant financial Minimum threshold of $10 000 generally applies to payments Minimum threshold of $5000 generally applies to payments interest or equity interests and/or equity interests Exclusions include income from seminars, lectures, Includes any equity interest in non-publicly traded entities or teaching, and service on advisory or review panels Exclusions include income from seminars, lectures, for public or nonprofit entities or teaching, and service on advisory or review panels for government agencies or institutions of higher education 
New Era of Transparency
The NIH looks forward to receiving comments from re searchers, institutions, industry, patients, and others who have an interest in or stand to be affected by the proposed rule changes. All stakeholder comments will be carefully con sidered during the process of drafting the final rules, which are expected to be issued before the end of this year. Capitalizing on innovation to benefit health requires a ro bust partnership that joins bias-free research with the most effective methods for translation and dissemination. As NIH strives to accelerate the movement of discoveries from the laboratory to the clinic, it is clear that already complex re lationships between NIH-funded researchers and industry will likely become more complicated, even as they become more exciting and more productive.
Consequently, for the good of the research enterprise and for our nation as a whole, it is imperative to take collective steps now to usher in a new era of clarity and transparency in the management of FCOI.
